Hansa Biopharma AB (publ) (FRA:24H)

Market Cap	307.78M
Revenue (ttm)	16.16M
Net Income (ttm)	-57.99M
Shares Out	n/a
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,546
Open	2.972
Previous Close	3.066
Day's Range	2.972 - 2.972
52-Week Range	1.732 - 3.786
Beta	n/a
RSI	64.43
Earnings Date	Feb 5, 2026

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 135
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 24H

Financial Performance

In 2024, Hansa Biopharma AB's revenue was 171.32 million, an increase of 27.76% compared to the previous year's 134.09 million. Losses were -807.24 million, -2.94% less than in 2023.

Financial numbers in SEK